Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 8Sinonasal undifferentiated carcinoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia 1Esthesioneuroblastoma, Olfactory 1Chondrosarcoma 1

Interventions

ruxolitinib 9fludarabine phosphate 8fludarabine 8Whole-Body Irradiation 8Specimen Handling 7Cytarabine 7Cyclophosphamide 7Mycophenolic Acid 6Tacrolimus 5Injections 5Busulfan 5Biopsy 5Azacitidine 5Stem Cell Transplantation 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Granulocyte Colony-Stimulating Factor 4CPX-351 4venetoclax 3luspatercept 3decitabine and cedazuridine drug combination 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporine 3Blood Specimen Collection 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3selinexor 2nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × enasidenib × 90 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡